As 2025 approaches, the United States faces another year of escalating Dengue fever outbreaks. However, a potential breakthrough may be on the horizon. A human monoclonal antibody (mAb) candidate from a Bethesda, MD-based company could soon secure FDA approval, offering new hope to travelers and patients alike.

Current Clinical Trial Status

As of February 12, 2025, the National Institutes of Health (NIH) and AbViro LLC are conducting a phase IIa clinical trial in Maryland and Vermont. This study involves exposing healthy volunteers to a weakened strain of the Dengue virus. Researchers are comparing three dose levels of AV-1 when challenged with DENV-3, the most transmissible strain of Dengue virus.

Objectives and Timeline

The trial commenced in early January 2025 and is scheduled for completion by autumn. This phase showcases the initial safety and efficacy of AV-1, setting the stage for further development.

The Dengue Ecosystem in the U.S.

Currently, the U.S. lacks approved Dengue vaccines or mAbs. This gap highlights the urgent need for effective treatments. Previous attempts, such as the Dengvaxia® vaccine, have faced setbacks and withdrawal from the U.S. market. Similarly, the market-leading second-generation vaccine, Qdenga, remains unapproved in the U.S.

FDA Approval and Future Implications

Should the AV1 vaccine candidate succeed, it would become the first FDA-approved treatment for Dengue fever. Such approval could revolutionize the medical landscape, providing healthcare providers with a critical tool to combat a severe and unpredictable disease.

Expert Opinion

Dr. Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases (NIAID), emphasizes the importance of developing new therapies. In a recent media release, she stated, “When caring for a patient who is critically ill with Dengue, healthcare providers have few options other than providing supportive care. We must find safe and effective therapeutics to provide much-needed relief to people suffering from Dengue.”

Vaccines vs. mAbs: A Comparative Advantage

While vaccines stimulate long-term immune response, mAbs offer rapid protection. This makes them particularly valuable for travelers and individuals at high risk of exposure. AbViro LLC’s AV-1 exemplifies the potential of mAbs in delivering rapid, targeted treatment.

Global Efforts: Dengushield

Developed by the Serum Institute of India Pvt. Ltd., Dengushield is another promising mAb in phase 3 trials. Dengushield inhibits all four types of dengue viruses and has shown safety and efficacy in phase 1 studies. Its development highlights the global collaboration needed to combat Dengue.

Dengue Risk in the U.S.

To mitigate risk, the CDC has issued Travel Health Advisories. Key regions reporting locally acquired dengue cases include Miami, Florida, and San Juan, Puerto Rico. As these areas become breeding grounds for Dengue-carrying mosquitoes, preventive measures are more critical than ever.

Preventive Strategies

Until an approved vaccine or mAb is available, the CDC advises travelers to avoid mosquito bites. Simple precautions, such as using insect repellents and wearing protective clothing, can significantly reduce the risk of contraction.

Conclusion

As the U.S. grapples with recurring Dengue outbreaks, the development of AV-1 and Dengushield represents a significant step forward. These treatments promise to offer much-needed relief and improved public health strategies.